CROSS-FILE ANALYSIS
Four peptides, four approval boundaries
A side-by-side evidence matrix built around mechanism, trial design, endpoint, and the exact scope of FDA review.
The comparison in plain English
All four compounds in this digest are peptides with human research records, and all four have an FDA-approved pharmaceutical context. That common fact is less informative than it sounds. Their receptors, endpoints, studied populations, and approved uses differ sharply.
Semaglutide and tirzepatide are incretin drugs with large metabolic trial programs. Tesamorelin works through the pituitary growth-hormone axis and is approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy [13]. PT-141 is better described as bremelanotide when referring to the approved product; its reviewed indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women [21].
The useful comparison asks five questions in order: What receptor does the peptide activate? What study design produced the claim? Which population was enrolled? What outcome was measured? What did the FDA actually approve? This approach prevents a narrow indication from becoming a broad wellness claim and keeps an impressive effect estimate tied to the trial that generated it.
Status matrix
| Compound | Primary mechanism | Strongest evidence in this corpus | FDA-status boundary | Principal cautions in this corpus |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Large randomized weight, cardiovascular, and kidney outcome trials [2][3][4] | Multiple approved prescription indications; each remains population- and product-specific | Gastrointestinal effects, biliary disease, boxed thyroid warning, retinopathy context [5][7] |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Placebo and active-comparator Phase 3 programs [1][10][11] | Approved metabolic and sleep-apnea indications in defined populations | Gastrointestinal tolerance, gallbladder or biliary signal, boxed thyroid warning [9][10] |
| Tesamorelin | GHRH receptor agonist; stimulates endogenous GH and IGF-1 | Randomized trials and a meta-analysis in HIV-associated lipodystrophy [12][14][16] | Approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy [13] | IGF-1 elevation, limited long-term oncologic data, fat reaccumulation after stopping [15][16] |
| PT-141 / bremelanotide | Central MC4R/MC3R agonist | Two Phase 3 trials plus a long-term extension [19][20] | Approved only for acquired, generalized HSDD in premenopausal women [21] | Nausea, transient blood-pressure increase, focal hyperpigmentation [20][21] |
Mechanisms are not interchangeable
The two incretin compounds share GLP-1 receptor activity, but tirzepatide adds GIP receptor agonism. In the direct SURMOUNT-5 comparison, that dual agonist produced greater average weight change than semaglutide over 72 weeks in 751 adults with obesity [1]. The result supports a comparative claim for that endpoint and trial population. It does not establish superiority on every outcome: semaglutide’s corpus also contains dedicated cardiovascular and kidney outcome trials [2][3].
Tesamorelin sits outside the incretin model. It acts at the pituitary GHRH receptor, increasing endogenous growth hormone and IGF-1. The clinical focus is visceral adipose tissue in HIV-associated lipodystrophy [12][14][16]. Bremelanotide occupies another system again, using central melanocortin signaling to affect sexual desire and arousal [18][19].
This mechanistic spread is why the site does not rank the four. A hazard ratio for a cardiovascular composite, a mean change in visceral-fat area, a percentage body-weight change, and a change on a desire scale answer different questions. Placing them in one numerical league table would create precision without meaning.
Evidence maturity and study design
Semaglutide has the largest outcomes studies in the set. SELECT included 17,604 participants and measured major cardiovascular events [3]; FLOW included 3,533 and measured a major kidney composite [2]. Tirzepatide’s evidence includes large weight and glycemic trials, plus direct comparisons [1][10][11]. These programs support broad evidence maturity, though each endpoint still has its own inclusion criteria and limitations.
Tesamorelin’s database is narrower by indication. A meta-analysis pooled five randomized studies [12], while a focused randomized trial included 50 adults with HIV [14]. The 52-week program demonstrates both sustained visceral-fat reduction during exposure and reaccumulation after discontinuation [16].
Bremelanotide combines pivotal randomized trials, an open-label extension, mechanistic neuroimaging, and preclinical work [17][18][19][20]. The randomized trials support the approved endpoint. The extension adds longer tolerability data. The neuroimaging and hamster studies refine possible pathways but do not substitute for the Phase 3 result. Evidence maturity is therefore multidimensional: size, randomization, comparator, duration, endpoint, and direct relevance to the approval question all matter.
What approval does—and does not—say
An FDA approval means a regulator reviewed evidence for a defined pharmaceutical product and use. It does not certify every possible use of the active molecule. Tesamorelin’s approval does not turn a trial in HIV-associated lipodystrophy into proof of general abdominal weight loss [13]. Bremelanotide’s approval does not cover men, postmenopausal women, or performance enhancement [21]. The broad approval portfolios of semaglutide and tirzepatide still remain tied to specific formulations, indications, and populations.
The same logic applies to supply. A product sold with a familiar peptide name outside the regulated system does not acquire the approved product’s identity, purity, concentration, or label. This is especially visible in PT-141 discussions, where the research code name can blur the line between bremelanotide as a prescription medicine and unverified research material.
The status verdict across the four is therefore neither simply “approved” nor “investigational.” The more accurate field is approved for what. The answer determines whether a claim sits inside the reviewed record, represents an off-label clinical question, remains investigational, or lacks agency review in the context being discussed.
Safety signals belong beside efficacy
The safety profiles also follow mechanism. GLP-1 activity commonly produces gastrointestinal effects, reflected in semaglutide and tirzepatide trials [5][10][11]. Both incretin records include gallbladder concerns; tirzepatide’s pooled analysis found an increased composite gallbladder or biliary risk but no statistically significant pancreatitis increase [9]. Semaglutide’s earlier cardiovascular trial identified a retinopathy-complication signal in a specific diabetes context [7].
Tesamorelin raises IGF-1 through the growth-hormone axis, so the review frame includes long-term growth-factor concerns and metabolic monitoring even though LiverTox considered clinically apparent liver injury unlikely [13][15]. Bremelanotide’s central melanocortin action produces a different profile: nausea, flushing, headache, transient blood-pressure elevation, and pigmentation changes [20][21].
Approval formalizes these cautions through labeling and surveillance; it does not mean adverse effects are negligible. Reading benefit and risk from the same study record keeps the comparison balanced and prevents efficacy endpoints from carrying more certainty than the safety data allow.